摘要
目的比较不同MTB抗原的酶联免疫斑点检测技术(ELISPOT)与各种影响因素的关系。方法对象对结核组132例和对照组44例观察对象应用PPD、克隆表达的早期分泌抗原靶6000(ESAT-6)和ESAT-6/培养滤液蛋白10000(CFP-10)融合蛋白(E/C)进行酶联免疫斑点检测(ELISPOT),检测外周血单个核细胞(PBMC)中经3种抗原刺激后斑点形成细胞(SFC)的数量。计量资料用中位数(四分位间距)表示,计量资料的比较采用Mann-Whitney u检验,计数资料的比较采用2χ检验。结果 E/C-ELISPOT在治疗时间>15 d病例形成的SFC数量少于治疗时间≤15 d形成的SFC数量。E/C-ELISPOT形成SFC数量与其他因素包括年龄、性别、病史等因素影响。PPD-ELISPOT和ESAT-6-ELISPOT形成SFC数量不受年龄、性别、病史、抗结核治疗时间等因素影响。3种抗原ELISPOT的敏感性不受年龄、性别、病史、抗结核治疗时间等因素影响。结论 ESAT6/CFP-10融合蛋白-ELISPOT形成的斑点数受治疗时间影响,可能成为监测抗结核治疗疗效的一项指标。
Objective To compare the effect of different Mycobacterium tuberculosis antigens on enzyme-linked immunospot assay （ELISPOT）. Methods 132 tuberculosis patients and 90 control cases were recruited to the research. The peripheral blood mononuclear cells （PBMC） of all participants were co-cultured with the following antigens： purified protein derivative （PPD）, early secretory antigenic target-6 （ESAT-6） and ESAT-6/culture filtrate protein-10 fusion protein （ESAT-6/ CFP-10, E/C）. Spot forming cells （SFC） were enumerated by ELISPOT. Tuberculin skin test was performed to all control participants. Results SFC count detected by ESAT-6/CFP-10 fusion protein ELISPOT were correlated with the duration of therapy. Conclusions ESAT-6/CFP-10 fusion protein-ELISPOT may act as a marker of antituberculous chemotherapy.
出处
《中国防痨杂志》
CAS
2010年第10期643-646,共4页
Chinese Journal of Antituberculosis
关键词
结核/诊断
抗原
细菌
细菌蛋白质类
重组融合蛋白质类
免疫酶技术
tuberculosis/diagnosis
antigens bacterial
bacterial protein
recombinant fusion pro teins
immunoenzyme techniques
